MPLT

MapLight Therapeutics, Inc. - Common Stock (MPLT)

About MapLight Therapeutics, Inc. - Common Stock (MPLT)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Details

Daily high

$11.93

Daily low

$11.08

Price at open

$11.20

52 Week High

$40.43

52 Week Low

$9.10

Market cap

479.2M

Dividend yield

Volume

5,434

Avg. volume

1.5M

P/E ratio

-2.20

MapLight Therapeutics, Inc. - Common Stock News